Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial to determine clinical outcomes in unresectable HCC patients who underwent treatment with atezolizumab and bevacizumab

Next Previous
Trial Profile

A clinical trial to determine clinical outcomes in unresectable HCC patients who underwent treatment with atezolizumab and bevacizumab

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
  • Indications Liver cancer
  • Focus Pharmacodynamics

Most Recent Events

  • 14 Jun 2024 New trial record
  • 10 Apr 2024 According to Results presented at the 115th Annual Meeting of the American Association for Cancer Research, the number of patients are small in this trial and accrual is still ongoing,

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top